S&P Futures
3,769.00 -52.25 (-1.37%) Dow Futures
30,636.00 -363.00 (-1.17%) Nasdaq Futures
11,506.25 -184.75 (-1.58%) Russell 2000 Futures
1,693.60 -27.80 (-1.61%) Crude Oil
109.23 -0.55 (-0.50%) Gold
1,811.50 -6.00 (-0.33%)
Natus Medical Incorporated (NTUS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 32.90 |
| Open | 32.84 |
| Bid | 32.04 x 1300 |
| Ask | 33.28 x 900 |
| Day's Range | 32.66 - 32.85 |
| 52 Week Range | 20.90 - 33.93 |
| Volume | |
| Avg. Volume | 531,341 |
| Market Cap | 1.131B |
| Beta (5Y Monthly) | 0.24 |
| PE Ratio (TTM) | 86.05 |
| EPS (TTM) | 0.38 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NTUS
Related Research
- Natus Medical IncorporatedNTUS: What does Argus have to say about NTUS?NATUS MEDICAL INC has an Investment Rating of BUY; a target price of $35.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.RatingFair ValueEconomic Moat8 days agoArgus Research
- GlobeNewswire
Natus Medical Announces First Quarter 2022 Financial Results
Q1-2022 Key ResultsRevenue (millions)$119.8 • Total revenue increased 4.2% compared to Q1 2021• Generated $8.9 million in operating cash flowGAAP EPS$0.06 Non-GAAP EPS$0.22 MIDDLETON, Wis., May 05, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three
- Barrons.com
Natus Medical Soars. It’s Being Taken Private by ArchiMed for $1.2 Billion.
Shares of Natus Medical were soaring Monday after the company announced it would be acquired by investment firm ArchiMed for approximately $1.2 billion. Natus (ticker: NTUS ) is a maker of medical devices for diagnosing and treating disorders affecting the brain and nervous systems. ArchiMed will pay Natus shareholders $33.50 in cash for each share of common stock they own, a 29% premium to the stock’s closing price on April 14.
